These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 21036884)
41. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925 [TBL] [Abstract][Full Text] [Related]
42. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Parthan A; Posner MR; Brammer C; Beltran P; Jansen JP Head Neck; 2009 Oct; 31(10):1255-62. PubMed ID: 19731394 [TBL] [Abstract][Full Text] [Related]
43. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650 [TBL] [Abstract][Full Text] [Related]
44. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Baghi M; Hambek M; Wagenblast J; May A; Gstoettner W; Knecht R Anticancer Res; 2006; 26(1B):585-90. PubMed ID: 16739325 [TBL] [Abstract][Full Text] [Related]
45. Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Recchia F; Saggio G; Cesta A; Amiconi G; di Blasio A; Candeloro G; Valeriani M; Tombolini V; Rea S Anticancer Res; 2006; 26(3B):2317-24. PubMed ID: 16821609 [TBL] [Abstract][Full Text] [Related]
46. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Posner M; Vermorken JB Semin Oncol; 2008 Jun; 35(3):221-8. PubMed ID: 18544437 [TBL] [Abstract][Full Text] [Related]
47. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Specenier P; Vermorken JB Curr Opin Oncol; 2007 May; 19(3):195-201. PubMed ID: 17414636 [TBL] [Abstract][Full Text] [Related]
48. [The role of taxanes for head and neck cancer]. Kohno N Gan To Kagaku Ryoho; 2005 Dec; 32(13):2035-9. PubMed ID: 16352925 [TBL] [Abstract][Full Text] [Related]
49. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Pignon JP; Syz N; Posner M; Olivares R; Le Lann L; Yver A; Dunant A; Lewin F; Dalley DN; Paccagnella A; Taylor SG; Domenge C; Bourhis J; Mazumdar M Anticancer Drugs; 2004 Apr; 15(4):331-40. PubMed ID: 15057136 [TBL] [Abstract][Full Text] [Related]
50. Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN). Kies MS Curr Treat Options Oncol; 2007 Jun; 8(3):252-60. PubMed ID: 17952388 [TBL] [Abstract][Full Text] [Related]
51. Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes. Sanders IW; Haslett K; Correa P; Paterson C; James A; Rizwanullah M; Grose D Scott Med J; 2014 Feb; 59(1):50-5. PubMed ID: 24424462 [TBL] [Abstract][Full Text] [Related]
52. How does TPF improve survival over PF? Pointreau Y; Atean I; Calais G Lancet Oncol; 2011 May; 12(5):420-1; author reply 421-2. PubMed ID: 21536219 [No Abstract] [Full Text] [Related]
53. EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Lalami Y; Specenier PM; Awada A; Lacombe D; Liberatoscioli C; Fortpied C; El-Hariry I; Bogaerts J; Andry G; Langendijk JA; Vermorken JB Radiother Oncol; 2012 Nov; 105(2):238-40. PubMed ID: 22989664 [TBL] [Abstract][Full Text] [Related]
54. Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis. Qin H; Luo J; Zhu YP; Xie HL; Yang WQ; Lei WB PLoS One; 2012; 7(12):e51526. PubMed ID: 23236511 [TBL] [Abstract][Full Text] [Related]
55. How does TPF improve survival over PF? Devisetty K; Wong SJ; Mell LK Lancet Oncol; 2011 May; 12(5):419-20; author reply 421-2. PubMed ID: 21536218 [No Abstract] [Full Text] [Related]
56. Current status and future directions in induction chemotherapy for head and neck cancer. Argiris A Crit Rev Oncol Hematol; 2013 Oct; 88(1):57-74. PubMed ID: 23541071 [TBL] [Abstract][Full Text] [Related]
57. [Effectiveness of concurrent chemoradiation therapy using TPF]. Yoshida T Gan To Kagaku Ryoho; 2010 Jul; 37(7):1244-9. PubMed ID: 20684090 [No Abstract] [Full Text] [Related]
58. Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology. Alterio D; Cossu Rocca M; Russell-Edu W; Dicuonzo S; Fanetti G; Marvaso G; Preda L; Zorzi S; Verri E; Nole' F; Jereczek-Fossa BA Med Oncol; 2017 May; 34(5):86. PubMed ID: 28391578 [TBL] [Abstract][Full Text] [Related]
59. [Docetaxel and squamous cell carcinoma of the head and neck]. Calais G Bull Cancer; 2004 Feb; 91(2):167-71. PubMed ID: 15047456 [TBL] [Abstract][Full Text] [Related]
60. Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Tousif D; Sarathy V; Kumar R; Naik R Front Oncol; 2020; 10():1284. PubMed ID: 32850394 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]